Anti-nr10 antibody and use thereof
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsTaichi Kuramochi, Keiko Kasutani, Souhei Ohyama, Hiroyuki Tsunoda, Tomoyuki Igawa, Tatsuhiko Tachibana, Hirotake Shiraiwa, Keiko Esaki
Life of this patent
Estimating the term…
Abstract
The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.
Claims159
1-13. (canceled)
A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs:
- 1-3, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs:
- 5-7, respectively.
A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 4.
A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 4 and a light chain variable region comprising SEQ ID NO:
- 8.
A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs:
- 9-11, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs:
- 13-15, respectively.
A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 12.
A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 12 and a light chain variable region comprising SEQ ID NO:
- 16.
A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs:
- 17-19, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs:
- 21-23, respectively.
A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 20.
A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 20 and a light chain variable region comprising SEQ ID NO:
- 24.
A purified anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs:
- 25-27, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs:
- 29-31, respectively.
A purified anti-NR10 antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 28.
A purified anti-NR10 antibody that binds to the same epitope bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 28 and a light chain variable region comprising SEQ ID NO:
- 32.
Nucleic acid of any one of (a) to (d) below:
- (a) nucleic acid encoding an antibody that recognizes domain 1 of NR10;
- (b) an isolated nucleic acid encoding a protein comprising the amino acid sequence of any one of SEQ ID NOs:
- 1-32;
- (c) an isolated nucleic acid encoding a protein that (i) comprises the amino acid sequence of any one of SEQ ID NOs:
- 1-32 in which one or more amino acids are replaced, deleted, inserted and/or added and (ii) binds to the same epitope as is bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 4 and a light chain variable region comprising SEQ ID NO:
- 8, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 12 and a light chain variable region comprising SEQ ID NO:
- 16, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 20 and a light chain variable region comprising SEQ ID NO:
- 24, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 28 and a light chain variable region comprising SEQ ID NO:
- 32;
- and
- (d) an isolated nucleic acid that (i) hybridizes under stringent conditions with the nucleotide sequence of any one of SEQ ID NOs:
- 1-32, and (ii) encodes a polypeptide that binds to the same epitope as is bound an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 4 and a light chain variable region comprising SEQ ID NO:
- 8, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 12 and a light chain variable region comprising SEQ ID NO:
- 16, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 20 and a light chain variable region comprising SEQ ID NO:
- 24, or by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 28 and a light chain variable region comprising SEQ ID NO:
- 32.
A method for producing an anti-NR10 antibody, the method comprising providing a cell containing recombinant nucleic acid encoding an antibody that recognizes domain 1 of NR10 and culturing the cell in vitro so that the antibody is expressed by the cell.
A composition comprising an antibody that recognizes domain 1 of NR10, the antibody being covalently linked to a molecule selected from the group consisting of a polymeric substance, hyaluronic acid, a radioactive substance, a fluorescent substance, a luminescent substance, an enzyme, and a toxin.
A method for measuring the activity of an anti-NR10 antibody, the method comprising contacting the antibody with cells of an interleukin 31 (IL-31)-dependent cell line and determining whether the antibody suppresses growth of the cells.
A method for determining the NR10-binding activity of an anti-NR10 antibody, the method comprising use of a technique selected from ELISA (enzyme-linked immunosorbent assay), EIA (enzyme immunoassay), RIA (radioimmunoassay) and fluorescent antibody assay to determine the NR10-binding activity of the anti-NR10 antibody.
A method for treating or preventing an inflammatory disease in a subject in recognized need thereof, the method comprising administering to the subject an antibody that recognizes domain 1 of NR10.
A method for isolating and purifying an antibody that recognizes domain 1 of NR10, the method comprising subjecting a sample comprising the antibody to a method comprising a combination of multiple techniques selected from column chromatography, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectrofocusing, dialysis, and recrystallization.
An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs:
- 196, 197, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs:
- 202, 170, and 193, respectively.
An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs:
- 9, 197 and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs:
- 202, 170, and 193, respectively.
An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs:
- 176, 197, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs:
- 202, 170, and 193, respectively.
An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs:
- 9, 198, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs:
- 202, 170, and 193, respectively.
An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs:
- 176, 198, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs:
- 202, 170, and 193, respectively.
An anti-NR10 antibody that comprises heavy chain variable region CDRs1-3 comprising SEQ ID NOs:
- 9, 199, and 184, respectively, and light chain variable region CDRs1-3 comprising SEQ ID NOs:
- 203, 170, and 193, respectively.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 206.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 207.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 208.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 209.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 210.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 211.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 212.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 213.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 214.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 215.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 216.
An anti-NR10 antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 217.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 224.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 225.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 226.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 227.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 228.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 229.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 230.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 231.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 232.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 233.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 234.
An anti-NR10 antibody that comprises a heavy chain comprising SEQ ID NO:
- 235.
An anti-NR10 antibody that comprises a light chain variable region comprising SEQ ID NO:
- 220.
An anti-NR10 antibody that comprises a light chain variable region comprising SEQ ID NO:
- 221.
An anti-NR10 antibody that comprises a light chain comprising SEQ ID NO:
- 238.
An anti-NR10 antibody that comprises a light chain comprising SEQ ID NO:
- 239.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 206 and a light chain variable region comprising SEQ ID NO:
- 220.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 207 and a light chain variable region comprising SEQ ID NO:
- 220.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 208 and a light chain variable region comprising SEQ ID NO:
- 220.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 209 and a light chain variable region comprising SEQ ID NO:
- 220.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 210 and a light chain variable region comprising SEQ ID NO:
- 220.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 211 and a light chain variable region comprising SEQ ID NO:
- 220.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 212 and a light chain variable region comprising SEQ ID NO:
- 220.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 213 and a light chain variable region comprising SEQ ID NO:
- 220.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 214 and a light chain variable region comprising SEQ ID NO:
- 220.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody that comprises a heavy chain variable region comprising SEQ ID NO:
- 215 and a light chain variable region comprising SEQ ID NO:
- 220.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 216 and a light chain variable region comprising SEQ ID NO:
- 221.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain variable region comprising SEQ ID NO:
- 217 and a light chain variable region comprising SEQ ID NO:
- 221.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 224 and a light chain comprising SEQ ID NO:
- 238.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 225 and a light chain comprising SEQ ID NO:
- 238.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 226 and a light chain comprising SEQ ID NO:
- 238.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 227 and a light chain comprising SEQ ID NO:
- 238.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 228 and a light chain comprising SEQ ID NO:
- 238.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 229 and a light chain comprising SEQ ID NO:
- 238.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 230 and a light chain comprising SEQ ID NO:
- 238.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 231 and a light chain comprising SEQ ID NO:
- 238.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 232 and a light chain comprising SEQ ID NO:
- 238.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 233 and a light chain comprising SEQ ID NO:
- 238.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 234 and a light chain comprising SEQ ID NO:
- 239.
A purified anti-NR10 antibody that binds to the same epitope as bound by an antibody comprising a heavy chain comprising SEQ ID NO:
- 235 and a light chain comprising SEQ ID NO:
- 239.
A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO:
- 1.
A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO:
- 9.
A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO:
- 17.
A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO:
- 25.
A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO:
- 196.
A purified anti-NR10 antibody comprising a heavy chain variable domain comprising a CDR1, a CDR2, and a CDR3, and a light chain variable domain comprising a CDR1, a CDR2, and a CDR3, wherein the heavy chain variable domain CDR1 comprises SEQ ID NO:
- 176.
A method of inhibiting the activity of NR10 comprising contacting the NR10 with an antibody that recognizes domain 1 of NR10.
A method of neutralizing the activity of interleukin 31 in a subject in recognized need thereof, the method comprising introducing into the subject an antibody that recognizes domain 1 of NR10.
A method for determining the NR10-binding activity of an antibody that recognizes domain 1 of NR10, the method comprising contacting the antibody with a polypeptide comprising domain 1 of NR10 and determining whether the antibody binds to the polypeptide.
A method for manufacturing an antibody that recognizes domain 1 of NR10, the method comprising making the antibody and assaying whether it binds to a polypeptide comprising domain 1 of NR10.
A method for manufacturing an antibody that recognizes domain 1 of NR10, the method comprising making the antibody and assaying whether it inhibits a biological activity of interleukin 31.
A hybridoma producing a glycosylated antibody that recognizes domain 1 of NR10.
A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising the heavy chain variable region of SEQ ID NO:
- 12.
A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:
- 9, 10, and 11, and a light chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:
- 13, 14, and 15.
A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising the heavy chain variable region of SEQ ID NO:
- 28.
A purified anti-NR10 antibody, wherein the antibody (i) is monoclonal or polyclonal, (ii) is glycosylated, and (iii) binds to the same epitope that is bound by a reference antibody comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:
- 25, 26, and 27, and a light chain variable region that comprises CDR1, CDR2, and CDR3 respectively comprising the amino acid sequences of SEQ ID NOs:
- 29, 30, and 31.
Dependencies are inferred from the claim text.